Cart
sales@molnova.com
Enfortumab
CAS No. 1448664-46-7
Enfortumab( —— )
Catalog No. M36881 CAS No. 1448664-46-7
Enfortumab is a monoclonal antibody against Nectin-4.Enfortumab can be used to synthesize antibody-drug couplings (enfortumab vedotin) and can also be used in conjunction with platinum compounds to study uroepithelial cancers.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 588 | In Stock |
|
| 10MG | 943 | In Stock |
|
| 25MG | 1397 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | 2492 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEnfortumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionEnfortumab is a monoclonal antibody against Nectin-4.Enfortumab can be used to synthesize antibody-drug couplings (enfortumab vedotin) and can also be used in conjunction with platinum compounds to study uroepithelial cancers.
-
DescriptionEnfortumab is a monoclonal antibody targeting Nectin-4. Enfortumab can used for researching urothelial cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorADC Antibody
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1448664-46-7
-
Formula WeightApproximately 143.9 kDa.
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Rosenberg JE, et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2019;37(29):2592-2600.
molnova catalog
related products
-
Leptin (22-56), huma...
Leptin(22-56),human is a peptide fragment of Leptin, which ACTS through a variety of subtypes of Ob-Rs.
-
ZEN-3862
ZEN-3862 is an inhibitor of BET(IC50s of 0.16 and 0.13 μM for BRD4(BD1) and BRD4(BD2) , respectively).
-
RJW100
RJW100 is a compound that acts as a potent agonist of liver receptor homolog 1 (LRH-1, NR5A2) and steroidogenic factor-1 (SF-1, NR5A1), exhibiting pEC50 values of 6.6 and 7.5, respectively.
